
Opinion|Videos|February 7, 2025
Jackson’s Journey with High Risk R/R MM
This segment highlights the treatment journey of a 68-year-old IT professional with high-risk multiple myeloma, detailing progression after initial D-RVd therapy, refusal of ASCT, and successful transition to cilta-cel CAR-T therapy with manageable adverse events.
Advertisement
This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with R/R MM as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
3
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
4
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
5


































